Seagen's deal – covering a drug candidate called LAVA-1223 – is in preclinical development and is designed to target and activate gamma delta T-cells in the presence of EGFR-expressing tumour ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback